Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990028 | 0.87 | KDM4E (0.56) | KDM4EPTGDR2HDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL2988654 | 0.86 | KDM4E (0.52) | KDM4EPTGDR2TSHRHDAC1HDAC6 | |
| SCHEMBL2989737 | 0.85 | KDM4E (0.60) | KDM4EPTGDR2NR1H4TSHR | |
| SCHEMBL2991646 | 0.85 | KDM4E (0.60) | KDM4EPTGDR2NR1H4NPC1PKM | |
| SCHEMBL2988774 | 0.85 | KDM4E (0.57) | KDM4EPTGDR2HDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL2994879 | 0.80 | KDM4E (0.58) | KDM4EPTGDR2NR1H4 | |
| SCHEMBL2982152 | 0.80 | KDM4E (0.53) | KDM4EPTGDR2HDAC6 | |
| SCHEMBL13742651 | 0.80 | KDM4E (0.72) | KDM4EPTGDR2NR1H4NPC1PKM | |
| SCHEMBL2977839 | 0.79 | MEN1 (0.55) | KDM4EPTGDR2SMN1; SMN2 | |
| SCHEMBL14301343 | 0.79 | KDM4E (0.50) | KDM4EPTGDR2NPC1PKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492437-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-07-23 | — | — | US | claimed |
| US-20120202854-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-08-09 | — | — | US | claimed |
| US-8492437-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492437-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2057115-B9 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2057115-B1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20120202854-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202854-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8183289-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183289-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183289-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | CD22, HRH2, CD74 | KDM4E 1078/4885PTGDR2 12/4885GRM4 282/4885 |
| US-20120202854-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | CD22, HRH2, CD74 | KDM4E 1078/4885PTGDR2 12/4885GRM4 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.